Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Chemical Constituents and Metabolites of Shipi Powder In Vitro and In Vivo Based on Ultra-High-Performance Liquid Chromatography Coupled With Quadrupole Time-of-Flight Tandem Mass Spectrometry.

Journal of separation science·2026
Same author

Development and validation of an interpretable model for pre-chemotherapy triage of fatigue-pain-sleep disturbance burden in lung cancer.

European journal of oncology nursing : the official journal of European Oncology Nursing Society·2026
Same author

Postpartum Depression and the Emerging Mother-Infant Relationship: Associations With Selective Serotonin Reuptake Inhibitor Medication Use.

JAACAP open·2026
Same author

Lithium-induced reconstruction of Li<sub>4</sub>Ti<sub>5</sub>O<sub>12</sub> for acidic H<sub>2</sub>O<sub>2</sub> production <i>via</i> two-electron water oxidation.

Chemical communications (Cambridge, England)·2026
Same author

Enhancing the ORR activity of Fe-based perovskite cathodes for intermediate-temperature solid oxide fuel cells: alternative strategies and performance optimization.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Bulk-heterojunction doping in lead halide perovskites for low-resistance metal contacts.

Nature materials·2026

Related Experiment Video

Updated: Jun 15, 2026

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Isolated polycystic liver disease.

Qi Qian1

  • 1Mayo Clinic College of Medicine, Rochester, MN 55905, USA. qian.qi@mayo.edu

Advances in Chronic Kidney Disease
|March 12, 2010
PubMed
Summary

Polycystic liver disease (PCLD) is an inherited condition causing liver cysts. While often asymptomatic, some patients face severe complications requiring symptom management.

Area of Science:

  • Hepatology
  • Genetics
  • Internal Medicine

Background:

  • Isolated polycystic liver disease (PCLD) is an autosomal dominant genetic disorder.
  • PCLD is characterized by liver cysts, with most patients being asymptomatic or subclinical.
  • A subset of patients experience severe complications like massive liver enlargement and cyst-related issues.

Purpose of the Study:

  • To summarize the current understanding of polycystic liver disease.
  • To highlight the clinical heterogeneity and complications associated with PCLD.
  • To outline the current management strategies for symptomatic PCLD.

Main Methods:

  • Literature review of PCLD genetics, clinical presentation, and management.
  • Analysis of patient data regarding disease progression and complications.

More Related Videos

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

Related Experiment Videos

Last Updated: Jun 15, 2026

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

  • Synthesis of current therapeutic approaches for symptomatic PCLD.

    • Main Results:

    • PCLD exhibits significant genetic and clinical variability.
    • Extrahepatic manifestations are uncommon in PCLD.
    • Symptomatic PCLD management focuses on palliation and complication treatment.

    Conclusions:

    • Polycystic liver disease requires careful monitoring due to potential severe complications.
    • Current management strategies are primarily supportive and palliative.
    • Further research may be needed to explore novel therapeutic avenues for PCLD.